New products, strong finances and robust growth were the main talking points at JP Morgan's recent healthcare conference in San Francisco. There were positive signals regarding the fundraising climate, as well as the strength of innovation within the sector.
Reporting season for 2016 is now getting under way and most companies should meet expectations. Good funding levels in the biotech sector, combined with low valuations and potentially favourable tax changes in the US, are expected to give takeover activity a big boost.
The recently announced acquisition of Ariad Pharma by Takeda and the Actelion takeover by Johnson & Johnson mark the beginning of this trend. Actelion has long been one of BB Biotech's core investments.
We believe mid-cap companies are likely to be where the action is over the next two to three years as they will be introducing innovative new therapeutic pathways to the marketplace. Oncology remains the largest therapeutic area covered by BB Biotech's portfolio.
While the share of portfolio assets invested in firms investigating infectious diseases will be slightly reduced due to recent setbacks in clinical trials with antibodies, we expect a growing number of new drug approvals in the field of neurological disorders this year. As such, we are confident our current portfolio strategy puts us in a good position to outperform the broader market in 2017
For more information, please contact:
Claude Mikkelsen
[email protected], +44 203 770 67 85 , www.bbbiotech.com
Disclaimer
All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.
